Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 999 West Broadway, Suite 720 VANCOUVER BC V5Z 1K5 |
Tel: | N/A |
Website: | https://www.essapharma.com |
IR: | See website |
Key People | ||
David Ross Parkinson President, Chief Executive Officer, Director | David Sidney Wood Chief Financial Officer | Peter Virsik Chief Operating Officer, Executive Vice President | Alessandra Cesano Executive Vice President, Chief Medical Officer |
Business Overview |
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology. |
Financial Overview |
For the three months ended 31 December 2023, ESSA Pharma Inc revenues was not reported. Net loss decreased 12% to $6M. Lower net loss reflects Investment and other income increase of 47% to $1.6M (income), Financing costs decrease from $2K (expense) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$0.15 to -$0.14. |
Employees: | 50 as of Sep 30, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $170.64M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$31.87M as of Dec 31, 2023 |
Net annual income (TTM): | -$25.80M as of Dec 31, 2023 |
Free cash flow (TTM): | -$21.57M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 44,238,147 as of Feb 12, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |